BAY-1816032
CAS No. 1891087-61-8
BAY-1816032( BAY1816032 )
Catalog No. M12963 CAS No. 1891087-61-8
BAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 87 | In Stock |
|
| 5MG | 73 | In Stock |
|
| 10MG | 122 | In Stock |
|
| 25MG | 242 | In Stock |
|
| 50MG | 351 | In Stock |
|
| 100MG | 500 | In Stock |
|
| 200MG | 686 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBAY-1816032
-
NoteResearch use only, not for human use.
-
Brief DescriptionBAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM.
-
DescriptionBAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM, displays excellent selectivity on a panel of 395 kinases; abrogates nocodazole-induced Thr-120 phosphorylation of the major BUB1 target protein histone H2A in HeLa cells with IC50 of 29 nM, induces lagging chromosomes and mitotic delay, inhibits proliferation of various tumor cell lines with mean IC50 of 1.4 uM; demonstrates synergy or additivity with paclitaxel or docetaxel both in vitro and in vivo.
-
In Vitro——
-
In Vivo——
-
SynonymsBAY1816032
-
PathwayAngiogenesis
-
TargetChk
-
RecptorChk
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1891087-61-8
-
Formula Weight534.524
-
Molecular FormulaC27H24F2N6O4
-
Purity>98% (HPLC)
-
SolubilityDMSO : 25 mg/mL 46.77 mM; H2O : < 0.1 mg/mL
-
SMILESCOC1=CN=C(N=C1NC2=C(C=NC=C2)OC)C3=NN(C4=CC=CC=C43)CC5=C(C=C(C=C5F)OCCO)F
-
Chemical Name2-[3,5-Difluoro-4-[[3-[5-methoxy-4-[(3-methoxy-4-pyridinyl)amino]-2-pyrimidinyl]-1H-indazol-1-yl]methyl]phenoxy]ethanol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gerhard Siemeister, et al. Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity. AACR. DOI: 10.1158/1538-7445.
2.?Siemeister G, et al. Clin Cancer Res. 2018 Nov 14. pii: clincanres.0628.2018.
molnova catalog
related products
-
MK 8776
MK 8776 (SCH 900776) is a potent and functionally selective CHK1 inhibitor (IC50=3 nM) with minimal intrinsic antagonistic properties.
-
Monalizumab
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).
-
PF-00477736
PF-00477736 (PF-477736) is a potent, selective, ATP-competitive inhibitor of Chk1 with Ki of 0.49 nM, also inhibits Chk2 (Ki=47 nM) and poorly inhibits CDK1 activity (Ki=9.9 uM).
Cart
sales@molnova.com